Bladder Cancer

Papers
(The TQCC of Bladder Cancer is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives10
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer9
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models8
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort8
Clinical Trials Corner Issue 8(1)8
Urologists and Advanced Practice Providers Evaluating Hematuria7
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer6
Clinical Trials Corner Issue 9(2)6
Antibiotics and BCG6
Standard vs extended lymphadenectomy for muscle invasive bladder cancer5
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter4
Management of bladder cancer in kidney transplant recipients: A narrative review4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder4
Clinical Trials Corner Issue 10(2)4
A New Standard of Care for Bladder Cancer4
Comparison of Robotic vs Open Cystectomy: A Systematic Review4
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract4
Organoid models in bladder cancer: From bench to bedside?4
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer3
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes3
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review3
Clinical Trials Corner Issue 7(3)3
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors3
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?2
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC2
Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab2
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Y Chromosome Loss and Bladder Cancer2
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets2
Challenging Cases in Urothelial Cancer: Case 272
Challenging Cases in Urothelial Cancer: Case 332
Challenging Cases in Urothelial Cancer: Case 262
Commentary on Novitas LCD2
Clinical Trials Corner Issue 8(2)2
0.044353008270264